Dyadic International Inc (DYAI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.52+3.89%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · DYAI
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -64.0% |
| Our one-year growth estimate | diamond | -60.0% |
Growth built into the price is above our model estimate.
The price assumes 4.0 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
DYAI — earnings miss
Dated 2026-08-12
Results of Operations and Financial Condition. On August 12, 2026, Dyadic International, Inc. (“Dyadic”) issued a press release announcing its results for the quarter ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18…
Why it matters: If the healthcare sector shows renewed growth, it could benefit Dyadic's performance. This would indicate a stronger market.
Supportive ifHealthcare sector revenue growth increases back toward 10% year over year.
Worry ifHealthcare sector revenue growth continues to slow below current levels.
Why it matters: Staying compliant is important for Dyadic's listing and for investor trust.
Supportive ifDyadic confirms it is still compliant with Nasdaq rules after the August offering.
Worry ifDyadic gets another notice of non-compliance from Nasdaq.
Why it matters: Getting funding gives money for operations and growth.
Supportive ifCompletion of the $2.9 million direct offering by August 14, 2026.
Worry ifFailure to complete the offering or delays in closing.
Why it matters: Earnings results will show if the company is doing better. Investors want to see profits.
Supportive ifThe earnings report shows smaller losses than before.
Worry ifThe earnings report shows losses getting bigger or staying the same.
Why it matters: Getting these payments shows progress in product development. This could help financial stability.
Supportive ifMilestone payments increase by more than $200,000 in the next quarter.
Worry ifMilestone payments do not increase or decrease in the next quarter.
Why it matters: More people using these platforms could lead to higher revenues. Management sees this as very important.
Supportive ifRevenue from C1 and Dapibus platforms increases by more than 20% quarter over quarter.
Worry ifRevenue from these platforms declines or grows less than 10% quarter over quarter.
Why it matters: Strong sales from AlbuFree™ DX would confirm the success of Dyadic's C1 platform in the market.
Supportive ifAlbuFree™ DX sales exceed $500,000 in the next quarter.
Worry ifSales from AlbuFree™ DX remain below $200,000 in the next quarter.
Why it matters: Staying compliant is key for Dyadic's stock stability. It helps keep investor trust.
Worry ifNo new notices of non-compliance from Nasdaq in the next quarter.
Less concerning ifDyadic gets another notice of delisting from Nasdaq.
Why it matters: Strong revenue growth shows that Dyadic's partnerships are working well.
Supportive ifQ3 revenue is over $1.1 million. This shows strong commercial use.
Worry ifQ3 revenue is under $1 million. This shows ongoing problems with commercialization.
Why it matters: Growth in revenue shows that products are selling well.
Supportive ifQ3 total revenue exceeds $961,138, the revenue reported for Q2 2026.
Worry ifQ3 total revenue is below $961,138. This shows ongoing issues with selling products.
Why it matters: Getting milestone payments shows Dyadic is making good progress with partners and products.
Supportive ifDyadic gets milestone payments of at least $500,000 from its partnerships.
Worry ifNo milestone payments are received in the next quarter.
Why it matters: This partnership could speed up vaccine and antibody development. This would help Dyadic's market position.
Supportive ifThere is news about new developments or milestones in the work with Scripps Research.
Worry ifNo updates or progress reported in the partnership with Scripps Research.
Why it matters: The company is at risk of being delisted. Compliance is critical for its future.
Worry ifThe company confirms it follows Nasdaq Listing Rule 5450(a)(1).
Less concerning ifThe company misses deadlines for compliance. It may also get another delisting notice.
Why it matters: Progress in partnerships could show the C1 platform can make money and help investors.
Supportive ifNew partnerships or progress in current partnerships for the C1 platform.
Worry ifNo news or delays in partnerships show no progress.
Why it matters: Getting milestone payments from BRIG Bio would show Dyadic can make money from its deals.
Supportive ifDyadic receives at least $100,000 in milestone payments from BRIG Bio.
Worry ifNo milestone payments are received from BRIG Bio in the next quarter.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$323 on $10,000 · ±3.2% | How much price usually moves either way. |
| Bad day | $771 loss on $10,000 · 7.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,594 loss on $10,000 · 65.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.